DRG Market Assessment reports

Painful diabetic neuropathy (PDN) is a prevalent complication of chronic diabetes, inducing enduring and often intense pain, characterized by sensations of burning, stabbing, tingling, and…

The angiogenesis inhibitor Erbitux, in combination with platinum-based therapy and 5-fluorouracil (5-FU), was the standard treatment option for all squamous cell carcinoma of the head and neck (…

Driven by DRG’s oncology expertise and real-world data capabilities, the Real World Brand Tracker is an interactive dashboard of regularly updated U.S. claims data that monitors and highlights…

Acute myeloid leukemia (AML) is associated with poor outcomes and low five-year overall survival rates. Although chemotherapy has long been the mainstay of AML treatment, the recent approval of new…

Neuromyelitis optica spectrum disorder (NMOSD) is a rare, chronic neuroinflammatory disorder that can lead to blindness and paralysis. Most patients have a relapsing form of the disease, leading to…

Myasthenia gravis (MG) is an acquired disorder of neuromuscular transmission, which occurs due to the production of pathogenic autoantibodies that bind to components of the neuromuscular junction,…

MARKET OUTLOOK The treatment landscape for psoriasis in the top 5 European markets (France, Germany, Italy, Spain, UK) is extremely dynamic. Humira (AbbVie), Enbrel (Amgen), Stelara (Janssen),…

Since 2018, seven novel drugs have entered the U.S. market for the acute or preventive treatment of migraine, and at least four more are on the short-term horizon. Understanding how prescribers…

The market for metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has great untapped potential owing to the disease’s high…

Clarivate Epidemiology’s coverage of endometrial cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key pemphigus vulgaris patient populations, covering 171 countries and…

Clarivate Epidemiology’s coverage of pemphigus vulgaris comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed prevalence and the…